Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cell Procurement

Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 39, pages 317–329 (2007)Cite this article

Abstract

Peripheral blood stem cells (PBSC) were mobilized in 130 patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation using cyclophosphamide 2 g/m2 and either granulocyte colony-stimulating factor (G-CSF) 5 mcg/kg/day (for systemic lupus erythematosus (SLE) and secondary progressive multiple sclerosis, SPMS) or G-CSF 10 mcg/kg/day (for relapsing remitting multiple sclerosis (RRMS), Crohn's disease (CD), systemic sclerosis (SSc), and other immune-mediated disorders). Mobilization-related mortality was 0.8% (one of 130) secondary to infection. Circulating peripheral blood (PB) CD34+ cells/μl differed significantly by disease. Collected CD34+ cells/kg/apheresis and overall collection efficiency was significantly better using Spectra apheresis device compared to the Fenwall CS3000 instrument. Patients with SLE and RRMS achieved the lowest and the highest CD34+ cell yields, respectively. Ex vivo CD34+ cell selection employing Isolex 300iv2.5 apparatus was significantly more efficient compared to CEPRATE CS device. Circulating PB CD34+ cells/μl correlated positively with initial CD34+ cells/kg/apheresis and enriched product CD34+ cells/kg. Mean WBC and platelet engraftment (ANC>0.5 × 109/l and platelet count >20 × 109/l) occurred on days 9 and 11, respectively. Infused CD34+ cell/kg dose showed significant direct correlation with faster white blood cell (WBC) and platelet engraftment. When adjusted for CD34+ cell/kg dose, patients treated with a myeloablative regimen had significantly slower WBC and platelet recovery compared to non-myeloablative regimens.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Fruehauf S, Haas R, Conradt C, Murea S, Witt B, Mohle R et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 1995; 85: 2619–2626.

    CAS  PubMed  Google Scholar 

  2. Roberts AW, Begley CG, Grigg AP, Basser RL . Do steady-state peripheral blood progenitor cell (PBPC) counts predict the yield of PBPC mobilized by filgrastim alone? Blood 1995; 86: 2451.

    CAS  PubMed  Google Scholar 

  3. Husson B, Ravoet C, Dehon M, Wallef G, Hougardy N, Delannoy A . Predictive value of the steady-state peripheral blood progenitor cell (PBPC) counts for the yield of PBPC collected by leukapheresis after mobilization by granulocyte colony-stimulating factor (G-CSF) alone or chemotherapy and G-CSF. Blood 1996; 87: 3526–3528.

    CAS  PubMed  Google Scholar 

  4. Breems DA, van Hennik PB, Kusadasi N, Boudewijn A, Cornelissen JJ, Sonneveld P et al. Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells. Blood 1996; 87: 5370–5378.

    CAS  PubMed  Google Scholar 

  5. Koc ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824–1830.

    Article  CAS  Google Scholar 

  6. Akard L . Optimum methods to mobilize stem cells. J Clin Oncol 2000; 18: 3063.

    Article  CAS  Google Scholar 

  7. Chabannon C, Le Corroller A-G, Viret F, Eillen C, Faucher C, Moatti J-P et al. Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. Leukemia 2003; 17: 811–820.

    Article  CAS  Google Scholar 

  8. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794.

    CAS  PubMed  Google Scholar 

  9. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059–2064.

    Article  CAS  Google Scholar 

  10. Deliliers GL, Annaloro C, Marconi M, Soligo D, Morandi P, Luchesini C et al. Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide. Leuk Lymph 2002; 43: 1957–1960.

    Article  CAS  Google Scholar 

  11. Mollee P, Pereira D, Nagy T, Song K, Saragosa R, Keating A et al. Cyclophosphamide, etoposide and G- CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Tranpslant 2002; 30: 272–278.

    Google Scholar 

  12. Petzer AL, Hochenburger E, Haun M, Duba HC, Grunewald K, Hoflehner E et al. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration. J Hematother Stem Cell Res 2002; 11: 293–300.

    Article  CAS  Google Scholar 

  13. Weaver CH, Birch R, Greco FA, Schwartzberg L, McAneny B, Moore M et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338–347.

    Article  CAS  Google Scholar 

  14. Yanovich S, Mitsky P, Cornetta K, Maziarz RT, Rosenfeld C, Krause DS et al. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplant 2000; 25: 1165–1174.

    Article  CAS  Google Scholar 

  15. Meehan KR, Slack R, Gehan E, Herscowitz HB, Areman EM, Ebadi M et al. Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients. J Hematother Stem Cell Res 2002; 11: 415–421.

    Article  CAS  Google Scholar 

  16. Prosper F, Sola C, Hornedo J, Arbona C, Menendez P, Orfao A et al. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuCSF and filgrastim in patients with breast cancer previously treated with chemotherapy. Leukemia 2003; 17: 437–441.

    Article  CAS  Google Scholar 

  17. Martin-Murea S, Voso MT, Hohaus S, Pforsich M, Fruehauf S, Golschmidt H et al. The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haematopoietic progenitor cells during marrow recovery. Br J Haematol 1998; 101: 582–585.

    Article  CAS  Google Scholar 

  18. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A et al. Mobilization of CD34+ cells in elderly patients (>70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413–423.

    Article  Google Scholar 

  19. Sevilla J, Gonzalez-Vicent M, Madero L, Garcia-Sanchez F, Diaz MA . Granulocyte colony-stimulating factor alone at 12 μg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplant 2002; 30: 417–420.

    Article  CAS  Google Scholar 

  20. Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155.

    CAS  PubMed  Google Scholar 

  21. Gordon PR, Leimig T, Mueller I, Babarin-Dorner A, Holladay MA, Houston J et al. A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant 2002; 30: 69–74.

    Article  CAS  Google Scholar 

  22. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048–3057.

    CAS  PubMed  Google Scholar 

  23. De Boer F, Drager AM, Van Haperen MJAM, Van der Wall E, Kessler F, Huijgens PC et al. The phenotypic profile of CD34-positive peripheral blood stem cells in different mobilization regimens. Br J Haematol 2000; 111: 1138–1144.

    Article  CAS  Google Scholar 

  24. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I . The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213–226.

    Article  CAS  Google Scholar 

  25. Shpall EJ, Champlin R, Glaspy JA . Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84–92.

    Article  CAS  Google Scholar 

  26. Gryn J, Shadduck RK, Lister J, Zeigler ZR, Raymond JM . Factors affecting purification of CD34+ peripheral blood stem cells using Baxter Isolex 300i. J Hematother Stem Cell Res 2002; 11: 719–730.

    Article  Google Scholar 

  27. Fruehauf S, Seggewiss R . It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement (review). Br J Haematol 2003; 122: 360–375.

    Article  CAS  Google Scholar 

  28. Burt RK, Verda L, Oyama Y, Statkute L, Slavin S . Non-myeloablative stem cell transplantation for autoimmune diseases. Springer Semin Immunopathol 2004; 26: 57–69.

    Article  Google Scholar 

  29. Sykes M, Nikolic B . Treatment of severe autoimmune disease by stem-cell transplantation. Nature 2005; 435: 620–627.

    Article  CAS  Google Scholar 

  30. Popat U, Krance R . Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br J Haematol 2004; 126: 637–649.

    Article  Google Scholar 

  31. Hough RE, Snowden JA, Wulffraat NM . Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol 2005; 128: 432–459.

    Article  CAS  Google Scholar 

  32. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthr Rheum 2006; 54: 3750–3760.

    Article  Google Scholar 

  33. McGonagle D, Rawstron A, Richards S, Isaacs J, Bird H, Jack A et al. A phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis. Arthr Rheum 1997; 40: 1838–1842.

    Article  CAS  Google Scholar 

  34. Snowden JA, Biggs JC, Miliken ST, Fuller A, Staniforth D, Passuello F et al. A randomized, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for hematopoietic stem cell mobilization in patients with severe active rheumatoid arthritis. Bone Marrow Transplant 1998; 22: 1035–1041.

    Article  CAS  Google Scholar 

  35. Breban M, Dougados M, Picard F, Zompi S, Marolleau J-P, Bocaccio C et al. Intensified-dose (4 g/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis. Arthr Rheum 1999; 42: 2275–2280.

    Article  CAS  Google Scholar 

  36. Locatelli F, Perotti C, Torretta L, Maccario R, Montagna D, Ravelli A et al. Mobilization and selection of peripheral blood hematopoietic progenitors in children with systemic sclerosis. Haematologica 1999; 84: 839–843.

    CAS  PubMed  Google Scholar 

  37. Burt RK, Fassas A, Snowden JA, van Laar JM, Kozak T, Wulffraat NM et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001; 28: 1–12.

    Article  CAS  Google Scholar 

  38. Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000; 54: 2147–2150.

    Article  CAS  Google Scholar 

  39. Euler HH, Harten P, Zeuner RA, Schwab UM . Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 1997; 24: 2153–2157.

    CAS  PubMed  Google Scholar 

  40. Gottenberg JE, Roux S, Desmoulins F, Clerc D, Mariette X . Granulocyte colony-stimulating factor therapy resulting in a flare of systemic lupus erythematosus: comment on the article by Yang and Hamilton. Arthr Rheum 2001; 44: 2458–2460.

    Article  CAS  Google Scholar 

  41. Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Farber L et al. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 1998; 22: 625–630.

    Article  CAS  Google Scholar 

  42. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–242.

    Article  CAS  Google Scholar 

  43. D'Arena G, Musto P, Di Mauro L, Cascavilla N, Iacono ND, Scalzulli PR et al. Predictive parameters for mobilized peripheral blood CD34+ progenitor cell collection in patients with hematological malignancies. Am J Hematol 1998; 58: 255–262.

    Article  CAS  Google Scholar 

  44. Demirer T, Buckner CD, Storer B, Lilleby K, Rowley S, Clift R et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 1997; 15: 684–690.

    Article  CAS  Google Scholar 

  45. Tarella C, Zallio F, Caracciolo D, Cherasco C, Bondesan P, Gavarotti P et al. Hematopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. Stem Cells 1999; 17: 55–61.

    Article  CAS  Google Scholar 

  46. Sautois B, Fraipont V, Baudoux E, Fassotte MF, Hermanne JP, Jerusalem G et al. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica 1999; 84: 342–349.

    CAS  PubMed  Google Scholar 

  47. Kudo Y, Minegishi M, Saito N, Itoh T, Fushimi J, Takahashi H et al. The absolute number of peripheral blood CD34+ cells predicts a timing for apheresis and progenitor cell yield in patients with hematologic malignancies and solid tumors. Tohoku J Exp Med 2003; 199: 111–118.

    Article  Google Scholar 

  48. Mehta J, Singhal S, Gordon L, Tallman M, Williams S, Luyun R et al. Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells. Bone Marrow Transplantation 2002; 29: 563–567.

    Article  CAS  Google Scholar 

  49. Hitzler WE, Wolf S, Runkel S, Kunz-Kostomanolakis M . Comparison of intermittent- and continuous-flow cell separators for the collection of autologous peripheral blood progenitor cells in patients with hematologic malignancies. Transfusion 2001; 41: 1562–1566.

    Article  CAS  Google Scholar 

  50. Despres D, Flohr T, Uppenkamp M, Baldus M, Hoffmann M, Huber C et al. CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACS device. J Hematother Stem Cell Res 2000; 9: 557–564.

    Article  CAS  Google Scholar 

  51. Schumm M, Lang P, Taylor G, Kuci S, Klingebiel T, Buhring HJ et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. J Hematother 1999; 8: 209–218.

    Article  CAS  Google Scholar 

  52. Weaver C, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.

    CAS  PubMed  Google Scholar 

  53. Kim I, Yoon SS, Lee K-H, Keam B, Kim TM, Kim J-S et al. Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies. Clin Transplant 2006; 20: 496–503.

    Article  Google Scholar 

  54. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Tripp-Villanueva F, Ayala-Sanchez M, Delgado-Lamas JL, Garces-Ruiz O et al. Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia. Stem Cells Dev 2004; 13: 571–578.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the Lupus Foundation of America, Illinois Chapter for their financial and patient support.

Author information

Authors and Affiliations

  1. Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    L Statkute, L Verda, Y Oyama, M Villa, T Shook, R Clifton, J Satkus, Y Loh, K Quigley, K Yaung, E Gonda, N Krosnjar, D Spahovic & R K Burt

  2. Maine General Medical Center, Waterville, ME, USA

    A Traynor

  3. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    B Jovanovic

Authors
  1. L Statkute
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Verda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Oyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Traynor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Villa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Shook
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Clifton
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Jovanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Satkus
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Y Loh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K Quigley
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K Yaung
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E Gonda
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. N Krosnjar
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. D Spahovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. R K Burt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R K Burt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Statkute, L., Verda, L., Oyama, Y. et al. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 39, 317–329 (2007). https://doi.org/10.1038/sj.bmt.1705579

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705579

Keywords

Search

Advanced search

Quick links